Krystal Biotech Inc (KRYS)

Net profit margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	57,161	10,932	-29,812	-140,409	-135,307	-139,975	-129,729	-115,468	-103,723	-69,570	-58,147	-52,168	-42,638	-32,167	-27,141	-21,803	-20,318	-19,088	-16,486	-14,490
Revenue (ttm)	US$ in thousands	102,227	56,573	9,365	809	809	0	0	0	0	0	0	0	0	0	0	0	542	1,125	1,342	1,515
Net profit margin		55.92%	19.32%	-318.33%	-17,355.87%	-16,725.22%	—	—	—	—	—	—	—	—	—	—	—	-3,748.71%	-1,696.71%	-1,228.46%	-956.44%

March 31, 2024 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $57,161K ÷ $102,227K
= 55.92%

The net profit margin of Krystal Biotech Inc has shown significant fluctuations over the past few quarters. In the latest quarter, ending March 31, 2024, the company achieved a net profit margin of 55.92%, which indicates that the company earned $0.5592 in profit for every $1 of revenue generated.

In the preceding quarter, the net profit margin was 19.32%, suggesting a decline from the previous quarter's profitability level. However, in the quarter ending September 30, 2023, the net profit margin was notably negative at -318.33%, reflecting that the company incurred significant losses exceeding its revenue.

The trend continues with even more substantial losses in the following quarters, including June 30, 2023, and March 31, 2023, where the net profit margin was -17,355.87% and -16,725.22% respectively. These extremely negative margins indicate that the company's expenses far exceeded its revenue during those periods, resulting in substantial net losses.

It is essential to investigate the underlying reasons for the negative net profit margins observed in the earlier quarters to understand the financial performance and sustainability of Krystal Biotech Inc. A thorough analysis of the company's cost structure, revenue streams, and operational efficiency is warranted to address the fluctuating profitability trends.